The recently found astounding efficacy of combined anti-CTLA-4 and anti-PD-1 therapy in advanced melanoma patients argues in favor of targeting multiple pathways for future immunotherapeutic approaches (167–169). This evidence concerns the gene PDCD1 and melanoma.